The latest research news in genetics and genomics.
The company said it will use proceeds from the round, which was led by Casdin Capital, to expand and commercialize its SomaScan platform and SomaSignal tests.
The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
For the three months ended Sept. 30, the firm said that total revenues fell to $1.2 million from $1.3 in the year-ago quarter with OVA1 volumes essentially flat.
